의료 분야 인지 기능 평가 및 트레이닝 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the cognitive assessment and training in healthcare market size is estimated at USD 11.46 billion in 2026, and is expected to reach USD 30.02 billion by 2031, at a CAGR of 21.25% during the forecast period (2026-2031).

This report is Segmented by Component (Solutions, Services), Assessment Type (Screening & Diagnostics, Clinical Trials, and More), Delivery Mode (Computer-Based and More), Application (Dementia & Alzheimer's, Traumatic Brain Injury, and More), End-User (Healthcare Providers, Payers and More), and Geography (North America and More). Market Forecasts are Provided in Terms of Value (USD).

Global Cognitive Assessment and Training In Healthcare Market Trends and Insights

Growing Prevalence of Neuro-Degenerative Disorders

Fifty-five million people were living with dementia in 2024, and the global tally is expected to climb to 78 million by 2030 and 139 million by 2050. Health systems are therefore shifting toward proactive cognitive screening at primary-care touchpoints. Early detection through digital tests slowed progression to moderate dementia by 18 months on average in 2025, saving USD 50,000 per patient in long-term care outlays. Pharmaceutical sponsors embed these tools in Phase II Alzheimer's trials to capture subtle efficacy signals and shorten timelines by up to nine months. The economic burden of dementia exceeded USD 1.3 trillion in 2024, galvanizing payer support for large-scale assessment programs that can defer costly institutional care. As a result, the Cognitive Assessment and Training in Healthcare market continues to benefit from both clinical urgency and economic incentives.

Rapid Adoption of Digital Health & mHealth Platforms

Twelve digital devices for cognitive testing cleared the FDA between January 2024 and December 2025, five of which run entirely on smartphones. Tele-neuropsychology sessions are reimbursed under CPT 96132 following Medicare's 2025 rule change, removing travel friction for patients in rural areas. The United Kingdom's MHRA now permits software-as-a-medical-device cognitive tools to rely on algorithmic equivalence rather than full clinical trials when predicates exist. Weekly at-home tests capture intra-individual variability that one-off clinic visits miss, enabling real-time therapy adjustments. This capability was pivotal in Biogen's 2024 lecanemab filing, where digital endpoints revealed treatment effects four months earlier than paper scales.

Data-Privacy & HIPAA / GDPR Compliance Burden

Average breach costs in healthcare reached USD 10.9 million in 2024, making longitudinal cognitive datasets an attractive ransomware target. GDPR treats cognitive data as special-category information, forcing vendors to adopt encryption and third-party audits. A vendor paid USD 4.8 million in HIPAA fines in 2024 after investigators uncovered lax access controls, damping venture funding for startups without mature compliance infrastructures. Smaller direct-to-consumer platforms often exit the European Union rather than absorb the 40-60% premium for GDPR-compliant hosting.

Other drivers and restraints analyzed in the detailed report include:

1. Regulatory Endorsement of Computerized Cognitive Tools
2. Rising CNS Clinical-Trial Spend for Cognitive End-Points
3. Limited Reimbursement Pathways

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Services revenue is projected to climb at 22.25% CAGR through 2031, closing the gap with Solutions, which held 61.55% share in 2025. Hospital networks cite shortages of neuropsychologists and data scientists, prompting outsourced contracts that bundle software, interpretation, and EHR integration. Solutions face margin compression from open-source alternatives, while Services command premium rates for actionable insights. The Cognitive Assessment and Training in Healthcare market size captured by Services is expected to surpass USD 14 billion by 2031 as value-based care models reward longitudinal tracking.

Managed-service leaders employ quality-assurance dashboards that flag anomalous scores in real time, a feature pharmaceutical sponsors now list as a top-three procurement criterion. Accountable care organizations integrate weekly cognitive updates into dementia pathways, triggering personalized interventions without clinician bottlenecks. As payer quality metrics evolve, hybrid vendors that combine platforms with expert interpretation will outpace pure-play software providers in the Cognitive Assessment and Training in Healthcare market.

Clinical Trials are on pace for a 22.15% CAGR, reflecting regulators' acceptance of smartphone-based cognitive endpoints. Screening & Diagnostics still commands the largest slice, yet reimbursement constraints will slow growth relative to trial demand. Sponsors budget generous per-test fees to cut enrollment timelines, allowing vendors to sustain margins above 65%. The Cognitive Assessment and Training in Healthcare market share attached to Clinical Trials could approach 25% by 2031.

Standardization delivers network effects: as more sponsors adopt the same digital battery, regulators become familiar with its psychometrics, further boosting credibility. CROs embed cognitive testing modules into turnkey offerings, making digital endpoints a default rather than an add-on. Academic consortia also adopt these tools for population studies, reinforcing the market flywheel.

Complete Report Scope:

• By Component
  • Solutions
  • Services
• By Assessment Type
  • Screening & Diagnostics
  • Clinical Trials
  • Academic & Research
• By Delivery Mode
  • Computer-based Testing
  • Mobile / App-based Testing
  • Pen-and-Paper
• By Application
  • Dementia & Alzheimer's
  • Traumatic Brain Injury
  • Learning Disabilities
  • Mental Health Screening
• By End-User
  • Healthcare Providers
  • Payers
  • Pharmaceutical & Biotech
  • Home-care & Patients
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.45% of 2025 revenue, anchored by Medicare's remote-testing coverage and the Veterans Health Administration's compulsory baseline screening for 9 million beneficiaries. Canada's Ontario province budgeted CAD 150 million through 2027 to digitize dementia testing, yet slower regulatory clearance tempers short-term gains. Mexico's 2025 dementia plan prioritizes screening, but limited smartphone penetration in rural districts curbs early uptake. Incumbents leverage payer networks and decades of validation data, presenting high entry barriers for newcomers in the North American Cognitive Assessment and Training in Healthcare market.

Asia-Pacific will deliver the fastest 22.22% CAGR to 2031. China mandates annual cognitive tests for adults aged 65+, a cohort of 190 million. India targets 50 million screenings by 2028 via primary-care health centers. Japan's aging demographics and JPY 30 billion digital health fund fuel home-based monitoring adoption. Australia boasts 42% penetration among memory clinics, but absolute volumes remain modest. South Korea's national dementia plan aims for 80% coverage by 2030, creating demand for platforms that handle 15 million annual assessments.

Europe, the Middle East, Africa, and South America form a heterogeneous landscape. Germany's low reimbursement and prior-authorization hurdles deter primary-care adoption. The U.K. has piloted digital testing across 50 clinics, yet budget constraints delay national rollout. France allocates EUR 400 million through 2029 for early detection infrastructure, including computerized tools. The UAE and Saudi Arabia include cognitive testing in digital health roadmaps, but limited population bases cap revenue potential. Brazil's public-sector rollout is stalled by fiscal austerity, while South Africa's private hospitals mirror European adoption rates. These disparities will keep EMEA and South America's combined Cognitive Assessment and Training in Healthcare market growth below the global average.

1. AnthroTronix
2. BrainCheck
3. BrainHQ
4. Cambridge Cognition
5. CogniFit
6. Cogstate
7. LearningRx
8. Lumos Labs
9. MedAvante-ProPhase
10. Neurotrack
11. NovaTech
12. Oxford University Press (CANTAB)
13. Pearson PLC
14. Posit Science
15. Savonix
16. Signant Health
17. VeraSci
18. WCG Clinical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing prevalence of neuro-degenerative disorders
  • 4.2.2 Rapid adoption of digital health & mHealth platforms
  • 4.2.3 Regulatory endorsement of computerized cognitive tools
  • 4.2.4 Rising CNS clinical-trial spend for cognitive end-points
  • 4.2.5 Integration with wearable neuro-biomarker ecosystems
  • 4.2.6 Employer-sponsored brain-wellness benefits
• 4.3 Market Restraints
  • 4.3.1 Data-privacy & HIPAA / GDPR compliance burden
  • 4.3.2 Limited reimbursement pathways
  • 4.3.3 Cultural / linguistic bias in AI algorithms
  • 4.3.4 Lack of harmonised clinical-validation standards
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces
  • 4.6.1 Supplier Power
  • 4.6.2 Buyer Power
  • 4.6.3 Threat of New Entrants
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Component
  • 5.1.1 Solutions
  • 5.1.2 Services
• 5.2 By Assessment Type
  • 5.2.1 Screening & Diagnostics
  • 5.2.2 Clinical Trials
  • 5.2.3 Academic & Research
• 5.3 By Delivery Mode
  • 5.3.1 Computer-based Testing
  • 5.3.2 Mobile / App-based Testing
  • 5.3.3 Pen-and-Paper
• 5.4 By Application
  • 5.4.1 Dementia & Alzheimer's
  • 5.4.2 Traumatic Brain Injury
  • 5.4.3 Learning Disabilities
  • 5.4.4 Mental Health Screening
• 5.5 By End-User
  • 5.5.1 Healthcare Providers
  • 5.5.2 Payers
  • 5.5.3 Pharmaceutical & Biotech
  • 5.5.4 Home-care & Patients
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AnthroTronix
  • 6.3.2 BrainCheck
  • 6.3.3 BrainHQ
  • 6.3.4 Cambridge Cognition
  • 6.3.5 CogniFit
  • 6.3.6 Cogstate
  • 6.3.7 LearningRx
  • 6.3.8 Lumos Labs
  • 6.3.9 MedAvante-ProPhase
  • 6.3.10 Neurotrack
  • 6.3.11 NovaTech
  • 6.3.12 Oxford University Press (CANTAB)
  • 6.3.13 Pearson PLC
  • 6.3.14 Posit Science
  • 6.3.15 Savonix
  • 6.3.16 Signant Health
  • 6.3.17 VeraSci
  • 6.3.18 WCG Clinical

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment